Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
0
-
Total 13F principal, excl. options
-
0
-
Principal change
-
-9.72M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$10.1M
-
Number of sells
-
-4
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2023
4 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2023.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 0 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $0 of principal
.
Largest 4 bondholders include UBS ASSET MANAGEMENT AMERICAS INC ($0 of principal), Congress Wealth Management LLC / DE / ($0 of principal), OAKTREE CAPITAL MANAGEMENT LP ($0 of principal), and WEDBUSH SECURITIES INC ($0 of principal).
This table shows the top 0 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.